Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: Effectiveness and cost

Ann Allergy Asthma Immunol. 2016 May;116(5):476-7. doi: 10.1016/j.anai.2016.03.008. Epub 2016 Mar 24.

Authors

Eva Rye Rasmussen¹, Lise Aagaard², Anette Bygum³

Affiliations

¹ Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address: eva.rye.rasmussen@dadlnet.dk.
² Department of Clinical Pharmacy, Institute of Public Health - Clinical Pharmacology, University of Southern Denmark, Odense, Denmark.
³ Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.

PMID: 27017563
DOI: 10.1016/j.anai.2016.03.008

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Angioedemas, Hereditary / drug therapy*
Bradykinin / analogs & derivatives
Bradykinin / therapeutic use
Bradykinin B2 Receptor Antagonists / therapeutic use
Complement C1 Inhibitor Protein / therapeutic use*
Complement Inactivating Agents / therapeutic use*
Female
Humans
Male
Middle Aged
Prospective Studies

Substances

Bradykinin B2 Receptor Antagonists
Complement C1 Inhibitor Protein
Complement Inactivating Agents
SERPING1 protein, human
icatibant
Bradykinin